89bio to Participate in the Leerink Partners Global Healthcare Conference

3/3/25 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ETNB alert in real time by email

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings.

The webcast of the fireside chat will be accessible in the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact:

Annie Chang

89bio, Inc.

[email protected]

PJ Kelleher

LifeSci Advisors, LLC

617-430-7579

[email protected]

Media Contact:

Sheryl Seapy

Real Chemistry

[email protected]

Get the next $ETNB alert in real time by email

Recent Analyst Ratings for

$ETNB

Date	Price Target	Rating	Analyst
3/14/2025	$11.00	Neutral	Goldman
3/13/2025	$25.00	Buy	Citigroup
2/4/2025		Outperform	Wolfe Research
4/22/2024	$30.00	Buy	BofA Securities
1/12/2024	$24.00 → $15.00	Outperform → Sector Perform	RBC Capital Mkts
10/10/2023		Outperform → Perform	Oppenheimer
8/28/2023	$36.00	Buy	UBS
6/13/2023	$49.00	Outperform	Evercore ISI

More analyst ratings

89bio to Participate in the Leerink Partners Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $ETNB

$ETNB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)

Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)

Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)

$ETNB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Le-Nguyen Quoc sold $91,208 worth of shares (15,329 units at $5.95), decreasing direct ownership by 4% to 328,323 units (SEC Form 4)

Officer Le-Nguyen Quoc was granted 14,750 shares and covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.30% to 343,652 units (SEC Form 4)

Chief Financial Officer Martins Ryan covered exercise/tax liability with 780 shares, decreasing direct ownership by 0.29% to 269,674 units (SEC Form 4)

$ETNB Financials

Live finance-specific insights

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

$ETNB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by 89bio Inc.

Amendment: SEC Form SC 13G/A filed by 89bio Inc.

Amendment: SEC Form SC 13G/A filed by 89bio Inc.

$ETNB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Goldman initiated coverage on 89bio with a new price target

Citigroup initiated coverage on 89bio with a new price target

Wolfe Research initiated coverage on 89bio

$ETNB Press Releases

Fastest customizable press release news feed in the world

$ETNB SEC Filings

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in Upcoming Investor Conferences

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.

SEC Form 10-Q filed by 89bio Inc.

89bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

$ETNB Leadership Updates

Live Leadership Updates

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

Recent Analyst Ratings for
$ETNB

$ETNB
Insider Purchases

$ETNB
Insider Trading

$ETNB
Financials

$ETNB
Large Ownership Changes

$ETNB
Analyst Ratings

$ETNB
Press Releases

$ETNB
SEC Filings

$ETNB
Leadership Updates